

Nonsteroidal Anti – inflammatory Drugs



Nonsteroidal Anti- Inflammatory Drugs

Non – narcotic / Non –opioid analgesics

- ◆ **Pain** – Two components
 - (i) **Peripheral component** – Nociceptive afferent neurons stimulated by noxious stimuli
 - (ii) **Central component** – Afferent inputs generate a pain sensation

Two types

Integumental pain

Visceral pain

NSAIDS

1. Not a steroid
2. Analgesic, Antipyretic, Anti-inflammatory
3. No CNS, RS depression
4. No Drug dependence
5. Act by inhibiting cyclo-oxygenase enzyme
decrease in PG Synthesis



◆ Classification of NSAIDS

1. Nonselective **irreversible** inhibitor of **cox**
Aspirin
2. Nonselective **reversible** inhibitor of **cox**
Ibuprofen, Flubriprofen, Indomethacin,
Mefenamic acid, Piroxicam, Ketorolac
3. **Preferential Cox-2** Inhibitors
Nimesulide, Meloxicam, Diclofenac, Acelofenac
4. **Selective Cox-2** inhibitors
Etoricoxib, Celecoxib, Parecoxib
5. **cox3** inhibitor
Paracetamol

Cyclo-oxygenase enzyme

- ◆ COX1-Constitutive form
- ◆ COX2-Inducible

Mechanism of action

Tissue injury \rightleftharpoons PG release \longrightarrow

- 1) mediators of inflammation, sensitize pain receptors at nerve endings.
- 2) Potentate action of other mediators at pain receptors – 5 HT, histamine, bradykinin ,TNFalfa ,IL .

NSAIDS-Inhibit COX ENZYME.

Inhibit synthesis of PGs from arachidonic acid

◆ **Aspirin**

Actions and Uses

- Oldest NSAID
- Converted in body to Salicylic acid

1 **Analgesia**

◆ Irreversible inhibitor of cox1, cox2 by acetylation of cox enzyme.

◆ Return of cox activity depends on synthesis of fresh enzyme

◆ PG synthesis



◆ Action of other inflammatory mediators



Use – 600 mg QID

Headache, Backache, Migraine, Toothache,
Myalgia, Dysmenorrhea

2. Antipyretic action

Fever d/t infection or inflammation-

- ◆ Bacterial endotoxins release IL1, TNFAlpha from macrophages- stimulates PGE₂ generation -↑ temp.
- ◆ Inhibit COX1, 2 - ↓ PG synthesis in hypothalamus -reset the hypothalamic thermostat.
- ◆ Aspirin doesn't inhibit heat production
- ◆ Increase heat loss-peripheral vasodilatation and sweating

Use- Treatment of fever of any origin

2. Anti – inflammatory effect

- 1 Cox- 2 - PGs → vasodilatation, oedema
2. Stabilizes leukocyte, lysosomal membrane
3. Leucocyte infiltration
4. Quenching of free radicals

Use – Dose -75-100 mg/kg/ day
Osteoarthritis
Rheumatoid arthritis
Rheumatic fever

3. Inhibition of platelet aggregation

- Irreversibly inhibits Cox-1 of platelets
- Acetylates Cox-1 of platelets in portal circulation before aspirin is deacetylated in liver

Small dose is sufficient as antithrombotic

- The enzyme is inhibited for life-time of platelets
- Decrease TXA2 production

Use –

- 1 Primary and secondary prevention of MI
2. Stroke
3. TIA

Low –Dose -75-325 mg/day

4. Relief of Dysmenorrhea

◆ level of $\text{PGF}_2\alpha$ -- uterine contraction –
Uterine ischemia – uterine cramps

◆ Normalizes excess flow

Use – Dysmenorrhea

5. Closure of Ductus Arteriosus

Kept patent in fetal life by PGE_2 , I_2

- Synthesis switched off at birth- ductus closes
- Small dose aspirin , endomethacin

Salicylic acid- Topical –keratolytic

Adverse effects

Gastric mucosal damage

1. Inhibition of cox 1 - ↓ PG synthesis -
↓ gastro-protective effect of PGs
S/E – dyspepsia, gastric Ulceration, gastric bleeding
2. Back diffusion of H⁺ ions
3. ↓ Secretions of HCO₃⁻
4. Local back diffusion of acid- focal necrosis of mucosal cells and capillaries

Mainly with anti-inflammatory dose

Less with selective cox-2 inhibitors

-Increase in bleeding tendency

- **prolongs bleeding time**

- **Aspirin to be stopped one week before surgery**

Precipitate bronchial asthma

Inhibition of cox – diversion of arachidonic acid to 5-Lipoxygenase pathway --- formation of leukotrienes

Renal Effects

- ◆ \downarrow uric acid excretion –by \uparrow uric acid secretion
- ◆ Impairment of renal bld flow
- ◆ COX2 dependent inhibition of Na^+ and water retention
- ◆ Papillary necrosis

- **Reye's syndrome**

- Rare
- Aspirin given to children suffering from febrile viral infection
- Liver damage, encephalopathy

Aspirin taken at term

delays onset of labour

Premature closure of ductus arteriosus

Drug interactions

with warfarin ,probenecid ,sufonyl ureas

with methotrexate

◆ Non – selective reversible

Propionic acid derivatives

Ibuprofen

Safest NSAID

Weak anti-inflammatory

Not suitable for acute conditions

400 mg TDS

Flurbiprofen

Eye – drops, gel

Naproxen

More efficacious as anti-inflammatory

better tolerated

Effectively inhibit Leucocytes

Use - osteoarthritis ,R.arthritis, gout

Dose-250 mg BD

Fenamates

Mephenamic acid

Analgesic, Antipyretic

Weak anti inflammatory

Use - Dysmenorrhea- 250mg -500mg TDS

S/E- Diarrhoea

Enolic acid derivatives

Piroxicam

- Lowers PG concentration in synovial fluid
- Decreases production of IgM rheumatoid factor
- Long acting.
- GIT S/E more common

Use – OA ,RA ,gout ,dentistry

- 20 mg OD

Acetic acid derivatives

Ketorolac analgesia = opioid

post operative pain

Musculoskeletal pain

Oral-10-20mg QID, parenteral

Indomethacin

- More potent than Aspirin

- More GIT upset ,Pancreatitis,

- CNS S/E-Headache, confusion, dizziness

- Reserve drug

- Ankylosing spondylitis, RA, Fever refractory to other antipyretics -25mg BD

- **Most common drug used for Closure of PDA**

- Eye drops, Mouth rinse-gingival inflammation

◆ Nabumetone

- Forms active metabolite

- Lower incidence of gastric irritation

500-1000 mg/day

Preferential COX-2 Inhibitors

Diclofenac sodium

- Most extensively used NSAID
- High concentration in synovial fluid, good tissue penetrability
- Gastric ulceration –less common ,more hepatotoxic and renotoxic
- 50 mg TDS, eye-drops, gel, inj
- use --RA ,OA, ankylosing spondylitis ,renal colic ,dysmenorrhea

Acelofenac

- Enhancement of glycosaminoglycan synthesis- chondroprotective property
- Long acting-100mg BD

Meloxicam

- less toxic than piroxicam

Nimesulide

- Sulfonamide compound
- Weak inhibitor of PG synthesis
- Reduced superoxide generation
- Free radical scavenging action
- Inhibition of PAF synthesis
- Withdrawn from some countries-

Hepatic failure

- Preferred in asthmatics, Intolerant to other NSAIDs

Selective Cox-2 inhibitors

- Called **coxibs**

- Less GIT side effects

- Rofecoxib, Valdecoxib – Withdrawn from market - Increase CVS, cerebro-vascular risk

Reduce whole body PGI₂ production without affecting TXA₂ contents in platelets (COX-2 absent in platelets)-prothrombotic effect

- Celecoxib-100-200 mg BD, Etoricoxib-60-90mg OD

- Preferred in patients –at risk of peptic ulcer, perforation d.t. low ulcerogenic potential

Paracetamol

Analgesics

Antipyretic

- Very less anti-inflammatory action-Inability to inhibit COX in presence of peroxides at inflammatory sites
- **Cox -3 New cox isoenzyme**
Abundant in cerebral cortex
Involved in pain perception, fever, not in inflammation
- **Paracetamol – Selective cox- 3 inhibitor**
- No gastric mucosal damage ,no stimulation of respiration, no platelet action

- Toxic dose of paracetamol

Hepatotoxicity – N acetyl- P Benzoquinoneimine

- Paracetamol metabolized by glucoronide conjugation. Small amount of toxic metabolite is formed by cytochrome P- 450 enzymatic system . It gets detoxified by glutathione conjugation.

Toxic dose- large amount of toxic metabolite is formed – Can't detoxified through glutathione conjugation.

- Form covalent bond with hepatic proteins
- Necrosis cell death

Treatment

N- acetyl cysteine – has SH group like glutathione – Replenish stores of glutathione and themselves conjugate with toxic metabolite.

150mg/kg I v infusion in 200ml of 5% dextrose over 15 mins., repeated for next 20 hrs.

- ◆ CI- Premature infants-risk of hepatotoxicity
- ◆ Use---common OTC drug
- ◆ Best Antipyretic, Analgesic

- ◆ **Choice of NSAIDS**
- ◆ **Combinations-additive**


Gout - acute arthritis

acute synovitis, ankle &
first MTP joints

Localized deposit of
monosodium urate
crystals



Hyperuricemia



hyperuricemia results when production exceeds excretion

Hyperuricemia - mechanisms


excessive
production

inadequate
excretion



hyperuricemia

Uric acid metabolism



Uric acid- poorly soluble - precipitated-deposited in cartilage of joints-inflammatory response to sodium urate crystals - infiltration of granulocytes-phagocytose - release glycoprotein - cartilage destruction

Drugs used to treat gout

Acute Arthritis Drugs

colchicine

steroids

NSAID's

Chronic gout :Urate Lowering Drugs

allopurinol

probenecid

Colchicine - plant alkaloid

colchicum autumnale

(autumn crocus or
meadow saffron)



Colchicine

- ◆ “only effective in gouty arthritis”
- ◆ not an analgesic
- ◆ does not affect renal excretion, production of uric acid

◆ Mechanism of action

- ◆ Inhibits migration of granulocytes to inflamed area and release of glycoprotein
- ◆ Binds to microtubules ,arrest division in metaphase

Adverse effects

- ◆ gastrointestinal -nausea, vomiting, cramps, diarrhea, abdominal pain
- ◆ hematologic -agranulocytosis, aplastic anemia, thrombocytopenia
- ◆ muscular weakness
- ◆ Dose 0.5-1.5mg/day

- ◆ **NSAIDs-** relieve acute attack
- ◆ Indomethacin
- ◆ Piroxicam
- ◆ Diclofenac
- ◆ Naproxen

Preferred over colchicine – better tolerated

Glucocorticoids

Intra-articular injection

Not responding to NSAIDs

Allopurinol



purine bases



hypoxanthine



xanthine




uric acid

alloxanthine



allopurinol

allopurinol
inhibits
xanthine
oxidase



Use

Chronic gout-First choice
100-300mg/day

To be given with NSAIDs to
prevent the acute attacks of
gouty arthritis

Probenacid

Uricosuric drug

Blocks tubular reabsorption of uric acid

Large amount of water –to be given

A/E- Dyspepsia

Sulphinpyrazone---- Not used

Febuxostat
Newer xanthine oxidase
inhibitor
40-80mg /day